Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB500 combination therapy in small cell lung cancer (phase II, China)
CTR20254756Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SKB500 in small cell lung cancer (SCLC), sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Primary endpoints: Incidence and severity of adverse events (AEs) and Progression-free survival (PFS) per RECIST v1.1 by investigator assessment. Started Jan 2026; status: active.
02
Drugs
SKB500
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20254756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254756.